secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunome Inc. (IMNM)
CIK:        0001472012
Form:       8-K
Filed at:   2024-03-28T23:59:59+00:00
Accession:  0001104659-24-040503
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunome posts FY2023 net loss of $106.8M; cash $138.1M, AL102 Phase 3 data due Q1 2025
--------------------------------------------------------------------------------

- Net loss $106.8M ($5.38 per share) for FY2023; cash and equivalents $138.1M as of Dec 31, 2023 (prior to Feb 2024 $230M offering).
- AL102 Phase 3 RINGSIDE topline data expected Q1 2025; IND filings for IM-1021 and IM-3050 expected Q1 2025.
- Closed acquisition of AL102 from Ayala (Mar 2024) and licensed IM-1021 from Zentalis (Jan 2024).
- Completed $230M underwritten offering in Feb 2024, extending cash runway into 2026.
- R&D expenses $23.1M, IPR&D $80.8M, G&A $19.7M for FY2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472012/000110465924040503/0001104659-24-040503-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472012/000110465924040503/tm2410047d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-040503

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer